CMOP.F Stock Overview
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF 80.25 |
52 Week High | CHF 80.25 |
52 Week Low | CHF 41.50 |
Beta | 1.24 |
11 Month Change | 0% |
3 Month Change | 0.31% |
1 Year Change | n/a |
33 Year Change | -16.41% |
5 Year Change | n/a |
Change since IPO | -50.06% |
Recent News & Updates
Recent updates
Shareholder Returns
CMOP.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -0.8% | -1.4% |
1Y | n/a | 18.5% | 16.9% |
Return vs Industry: Insufficient data to determine how CMOP.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CMOP.F performed against the US Market.
Price Volatility
CMOP.F volatility | |
---|---|
CMOP.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CMOP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CMOP.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 325 | Giovanni Di Napoli | www.cosmopharma.com |
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, a submucosal injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin SV MMX – IBS-D, a formulation that is in Phase III clinical trial to treat colonic infections and irritable bowel syndrome with diarrhoea; CB-03-10, an oral androgen receptor antagonist, which is in Phase I clinical trial for treatment solid tumors; CB-01-33 that is in preclinical studies for the treatment of bile acid diarrhea; and CB-01-35, an enema solution, which is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
CMOP.F fundamental statistics | |
---|---|
Market cap | US$1.28b |
Earnings (TTM) | US$75.54m |
Revenue (TTM) | US$201.26m |
17.0x
P/E Ratio6.4x
P/S RatioIs CMOP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CMOP.F income statement (TTM) | |
---|---|
Revenue | €185.36m |
Cost of Revenue | €43.62m |
Gross Profit | €141.74m |
Other Expenses | €72.16m |
Earnings | €69.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 4.33 |
Gross Margin | 76.47% |
Net Profit Margin | 37.53% |
Debt/Equity Ratio | 0.3% |
How did CMOP.F perform over the long term?
See historical performance and comparison